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Background: Human papillomavirus (HPV) is estimated to play an etiologic role in 40–50%
of penile cancers worldwide. Estimates of HPV prevalence in U.S. penile cancer cases are
limited.
Methods:HPV DNA was evaluated in tumor tissue from 79 invasive penile cancer patients
diagnosed in 1998–2005 within the catchment areas of seven U.S. cancer registries. HPV
was genotyped using PCR-based Linear Array and INNO-LiPA assays and compared by
demographic, clinical, and pathologic characteristics and survival. Histological classification
was also obtained by independent pathology review.
Results: HPV DNA was present in 50 of 79 (63%) of invasive penile cancer cases. Sixteen
viral genotypes were detected. HPV 16, found in 46% (36/79) of all cases (72% of HPV-
positive cases) was the most prevalent genotype followed equally by HPV 18, 33, and 45,
each of which comprised 5% of all cases. Multiple genotypes were detected in 18% of viral
positive cases. HPV prevalence did not significantly vary by age, race/ethnicity, population
size of geographic region, cancer stage, histology, grade, penile subsite, or prior cancer
history. Penile cases diagnosed in more recent years were more likely to be HPV-positive.
Overall survival did not significantly vary by HPV status.
Conclusion: The relatively high prevalence of HPV in our study population provides lim-
ited evidence of a more prominent and, possibly, increasing role of infection in penile
carcinogenesis in the U.S. compared to other parts of the world.
Keywords: human papillomavirus, HPV, prevalence, penile cancer, United States
INTRODUCTION
The annual, average age-adjusted incidence of invasive penile can-
cer in the U.S. is less than 1 per 100,000, which represents less
than 0.5% of all cancers in men (1). Penile cancer incidence varies
globally, with lower incidence in the United States and other West-
ern countries and comparably higher incidence in parts of Africa,
Southeast Asia, and Latin America (2, 3). Human papillomavirus
(HPV) likely represents a distinct etiologic pathway of penile car-
cinogenesis (4). Worldwide, HPV is estimated to play an etiologic
role in 40–50% of penile cancers (2, 3, 5). HPV 16 is the most
frequently detected genotype in penile tumors (2, 6, 7). Other risk
factors for penile cancer include cigarette smoking, lack of circum-
cision, poor hygiene, and phimosis (4, 8–11). The extent to which
worldwide differences in penile cancer incidence are attributed to
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variation in HPV prevalence is unknown. There is some evidence
of regional differences in HPV prevalence in penile tumors (2).
To date, however, there are limited estimates of the prevalence of
HPV in U.S. penile cancer patients. In U.S. studies, including small
case series from single institutions and single geographic regions,
prevalence ranged from 31 to 82% (12–15).
MATERIALS AND METHODS
We conducted a study to evaluate the genotype-specific HPV
distribution in invasive penile cancer cases from the U.S. and
to compare the viral status of cases by demographic, clinical,
and pathologic characteristics. This evaluation was part of a
larger initiative by the Centers for Disease Control and Pre-
vention (CDC) to examine HPV genotype distribution among
anogenital and select head and neck cancer sites for cases diag-
nosed in the United States prior to the implementation of
widespread HPV prophylactic vaccination (16). This study was
approved by the institutional review boards overseeing the CDC
and participating cancer registries. Invasive penile cancer cases
were defined based on the International Classification of Dis-
eases for Oncology Version 3 (17). Cases were selected from
patients with histologically confirmed invasive penile cancer
who were diagnosed in Kentucky, Louisiana, Michigan, Iowa,
Hawaii, and Los Angeles County. Additionally, Florida included
a three-county catchment area. Penile cancer cases from Iowa,
Hawaii, and Los Angeles County were selected from those with
archival tissue in existing tissue repositories. The three resid-
ual tissue repositories (RTR) (18) are a part of the National
Cancer Institute’s (NCI) surveillance, epidemiology, and end-
results (SEER) program and consist of collections of deidentified
formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens
obtained from area pathology laboratories. Penile cancer cases
from Florida, Kentucky, Louisiana, and Michigan were sampled
from all invasive cases diagnosed in 2004–2005 with available
FFPE tissue from area pathology laboratories. Penile cases from
Hawaii included all RTR cases diagnosed in 2000–2004; Iowa and
Los Angeles County cases included those diagnosed in 1998–
2000. A total of 163 penile cancer cases were initially identi-
fied across the seven registries and tumor tissue specimens were
available for 90.
Formalin-fixed paraffin-embedded tissue specimens from the
90 cases were prepared at central laboratories servicing each reg-
istry or medical facility following a uniform protocol. As pre-
viously detailed, one representative block from each case was
prepared using procedures to minimize the risk of sample-to-
sample contamination (16). Sections were prepared from each
block using a new disposable blade for each case. The first and
last sections were stained with hematoxylin and eosin (H&E)
and intervening sections were transferred into 2 ml conical tubes
(Simport, Beloeil, Canada). Prepared FFPE tissues were sent to
the CDC. H&E sections were reviewed by a study pathologist
(Elizabeth R. Unger) to confirm the presence of malignancy.
The first H&E slide was digitized using ScanScope XT (Ape-
rio Technologies, Vista, CA, USA) at 0.25 hm per pixel resolu-
tion, equal to 40× objective. Of the 90 cases prepared, 5 lack-
ing adequate tumor tissue and 2 with only in situ components
were excluded.
Tissue from the remaining 83 cases was genotyped. One
suitable tissue sample from each case was processed as pre-
viously described using high temperature assisted tissue lysis
(19) and automated DNA purification with a Chemagic MSM1
(PerkinElmer, Waltham, MA, USA). The resulting 100µl DNA
elute was tested immediately or stored at −20°C until testing. A
blank sample without tissue was included in every sample batch
to monitor potential cross contamination. All DNA extracts were
tested with the Linear Array HPV Genotyping Test (LA, Roche
Diagnostics, Indianapolis, IN, USA), which distinguishes 37 dif-
ferent HPV genotypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
52 (XR), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72,
73, 81, 82, 83, 84, 89, IS39). Templates for the PCR reaction were
prepared with 10µl DNA and 40µl H2O, otherwise following the
manufacturer’s protocol. The reverse line-blot hybridization was
performed with an automated platform; Beeblot instruments (Bee
Robotics, Caernarfon, UK). Samples with negative or inadequate
LA results were re-tested with the INNO-LiPA HPV Genotyping
Assay (LiPA, Innogenetics, Gent, Belgium), which detects 29 HPV
types including three types not covered by the Linear Array (43,
44, 74,) and performs a generic probe to identify other HPVs not
on the array (HPV X). The assay was performed according to the
manufacturer’s specifications using an Autoblot 3000 (MedTec,
Buffalo Grove, IL, USA) for the line-blot procedure. Both typing
assays included an endogenous positive control for the presence
of amplifiable DNA. Samples negative for HPV and for the con-
trol probe in both assays were considered inadequate. Of the 83
penile cancer cases genotyped, 4 yielded inadequate results and
were excluded.
A total of 79 cases were retained in the statistical analyses. Dei-
dentified demographic (age, sex, population size), clinical (year
of diagnosis, history of other cancers), pathologic (subsite, stage,
grade), and outcome data (vital status, cause of death, survival
time) were available from each registry. Stage was based on the
SEER staging classification system (20). A large number of cases
were histologically classified as unspecified squamous cell carci-
noma (SCC). To improve the reliability of histological classifica-
tion, digital images of all cases were reviewed and re-classified by
one pathologist (Amy Powers) who was blinded to clinical and
pathologic information as well as HPV status of cases.
Statistical analyses were conducted using SAS version 9.2. All
tests were two-sided and a p-value of 0.05 was considered to be
statistically significant. Overall HPV prevalence was based on the
detection of one or more HPV genotypes in tumor tissue. Mul-
tiple genotypes detected in a case were not counted more than
once in prevalence estimates. HPV 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, and 68 were considered high-risk genotypes
(21). All other genotypes were considered to be of low or unde-
termined risk. Age was imputed to the mid-point of 5 year age
groups for three cases from whom single year age was not available.
Race/ethnicity was classified as non-Hispanic white, non-Hispanic
black, Hispanic, and other. Comparisons by HPV status were made
using the Chi-square test for discrete variables. Overall survival
of HPV-positive and HPV-negative patients was compared using
Kaplan–Meier and multivariable Cox regression analyses. Survival
analyses excluded five cases for which vital status and survival time
were not available.
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Table 1 | Genotype distribution of HPV DNA-positive invasive penile
cancer cases (n=50).
HPV types Number of cases
6 1
16a 29
18a 2
33a 3
35a 1
42 1
45a 2
52a 1
6, 16a 1
16a, 45a 1
16a, 55 1
16a, 58a 1
16a, 18a, 72 1
16a, 18a, 31a, 58a, 73 1
16a, 45a, 55 1
33a, 62 1
35a, 53, 59a 1
Xb 1
aHigh-risk types; all others are considered to be of low or undetermined risk.
bHPV-positive for none of the 40 types assayed.
RESULTS
Human papillomavirus DNA was detected in 50 of 79 (63%) inva-
sive penile cancer cases. A total of 16 genotypes were detected
(Table 1). HPV 16 was the most prevalent genotype comprising
72% (36/50) of HPV-positive cases, or 36 of 79 (46%) of all cases.
Other high-risk types detected were HPV18, 31, 33, 35, 45, 52,
58, and 59. Two tumors were solely positive for low-risk types,
HPV 6 and HPV 42, respectively. In total, genotypes other than
HPV 16 or 18 were prevalent in 12 of 79 (15%) cases, or 24%
of all HPV-positive tumors. One case was not positive for the 40
genotypes assayed and was designated HPV X. Multiple genotypes
were found in 18% (9 of 50) of HPV-positive cases; HPV 16 was
detected in 7 of these 9 cases.
Demographic and clinical characteristics of the 79 invasive
penile cancer cases study cases in the study sample were com-
parable to that of all registry cases diagnosed over the same time
period (data not shown). Study cases spanned a wide age range;
33–100 years (mean 70.9± 14.8). Whites comprised 56% of cases
followed by blacks (24%), and Hispanics (17%). The large major-
ity of cases were diagnosed in 2004–2005 (86%). Most cases were
localized, early stage tumors (67%), and of moderately differenti-
ated grade (51%). Thirty-two percent of tumors were of the glans
or prepuce. A prior history of cancer was reported in 43% of cases;
information on type of cancer was not available. Based on registry
data, 61 of the 79 (76%) cases were histologically classified as SCCs
not otherwise specified (SCC NOS), 17 were keratinizing SCC and
1 verrucous SCC. NOS cases consisted of those without histologi-
cal subtype documented in the pathologic record. Following inde-
pendent pathologic review, cases were re-classified as keratinizing
SCC (n= 53), basaloid SCC (n= 3), warty SCC (n= 3), mixed
basaloid-keratinizing SCC (n= 4), mixed warty-keratinizing SCC
Table 2 | Characteristics of invasive penile cancer cases by HPV status
(n=79).
Characteristicsa HPV− (n=29) HPV+ (n=50) Pb
No. %c No. %c
AGEAT DIAGNOSIS (YEARS)
Mean (SD) 72.7 (SD
15.3)
69.8 (SD
14.5)
0.40
<60 4 21.1 15 78.9 0.27
60–79 14 41.2 20 58.8
≥80 11 42.3 15 57.7
RACE/ETHNICITYd
White 15 37.5 25 62.5 0.77
Black 5 29.4 12 70.6
Hispanic 5 41.7 7 58.3
POPULATION SIZE OF RESIDENCE
<20,000 16 32.0 34 68.0 0.42
20,000–250,0000 3 33.3 6 66.7
250,000≥1,000,000 8 50.0 8 50.0
YEAR OF DIAGNOSIS
1998–2003 7 63.6 4 36.4 0.05
2004–2005 22 32.4 46 67.6
STAGEe
Localized 15 31.9 32 68.1 0.10
Regional or distant metastasis 12 52.2 11 47.8
HISTOLOGYf
Keratinizing SCC 23 43.4 30 56.6 0.19
Basaloid or warty SCCg 2 18.2 9 81.8
Other SCC 4 26.7 11 73.3
TUMOR GRADE
Well-differentiated 10 43.5 13 56.5 0.46
Moderately differentiated 12 34.3 23 65.7
Poorly differentiated 6 54.5 5 45.5
SUBSITE
Glans/prepuce 10 40.0 15 60.0 0.68
Other or unspecified 19 35.2 35 64.8
HISTORY Of OTHER CANCERS
No 16 35.6 29 64.4 0.81
Yes 13 38.2 21 61.8
aMissing data: race/ethnicity (n=7); population size of residence (n=4); stage
(n=9); grade (n=10).
bChi-square test comparing HPV− and HPV+.
c% Of total for each variable category (row).
dWhites and blacks include non-Hispanics only; Asians excluded due to frequen-
cies <5.
eStage classified according to SEER Summary Stage 2000.
fBased on independent review by one pathologist.
gIncludes tumors with basaloid or warty types combined with other histologies.
(n= 1), and verrucous SCC (n= 1); 13 remained SCC NOS
(n= 13).
The detection of HPV (any genotype) in penile cancers did not
significantly vary by age, race/ethnicity, population size of geo-
graphic region, stage, histology, grade, penile subsite, or cancer
history (Table 2). Of penile cancers diagnosed during the most
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FIGURE 1 | Overall survival of invasive penile cancer cases by HPV
status: any HPV+ (n=48) vs. HPV− (n=26) Log-rank p-value=0.37.
recent time period (2004–2005), 68% were HPV-positive com-
pared with 36% of cases diagnosed in 1998–2003 (p= 0.05). In
order to evaluate the possible influence of the age of specimens on
the detection of HPV, we compared the number of samples with
negative or inadequate results generated from the linear array test
requiring retesting with the second assay by period of diagnosis.
Four of 11 cases diagnosed in 1998–2003 were derived by LiPA
compared to 10 of 67 cases diagnosed in 2004–2005 (p= 0.09).
Survival analyses included 74 of the 79 penile cancer cases; 5
cases without available outcome data were excluded. Overall sur-
vival was 60% for HPV-positive cases and 50% for HPV-negative
cases (log-rank p-value= 0.37) (Figure 1). Survival did not vary
significantly by HPV status when limited to high-risk types or
HPV 16 alone (data not shown). Proportional hazards assump-
tions were met. For any HPV, the unadjusted hazard ratio was
0.73, 95% CI 0.37–1.45. After adjustment for age, stage, and year
of diagnosis, the hazard ratio was 0.86, 95% CI 0.40–1.86. In both
univariate and multivariate models, high-risk HPV and HPV 16
status did not predict survival (data not shown).
DISCUSSION
This is the first study of HPV prevalence in invasive penile can-
cer cases drawn from diverse regions of the U.S., including those
with large Hispanic, black, and Asian populations. Although not
a representative sample of the entire U.S. population, cases came
from seven cancer registries covering defined geographic regions
of the country, including five registries with statewide coverage.
The overall HPV prevalence of 63% in this U.S. sample is higher
than estimates of HPV prevalence in penile cancers worldwide (2,
3, 5). Two reviews of published studies of penile cancers diag-
nosed worldwide in 1986–2008 found an overall HPV prevalence
of 47–48% (2, 5). Differences in the sensitivity of laboratory
methods may account for a higher prevalence in our study pop-
ulation. Notably, the present study utilized methods designed to
enhance DNA isolation from fixed, archival tissue, and two sep-
arate PCR-based genotyping assays detecting a broad range of
HPV genotypes. HPV prevalence may have also been influenced
by unmeasured factors specific to the study population such as
sexual risk factors and circumcision status.
Our findings agree with previous studies demonstrating HPV
16 to be the predominant genotype in penile cancers (2, 6, 7). HPV
16 and 18, the two high-risk types covered by current prophylactic
vaccines, were identified in nearly half of the tumors. The poten-
tial role of other genotypes in penile carcinogenesis is underscored
by the detection of 14 other types, including those considered to
be low-risk. The detection of low-risk types HPV 6 and 42 alone
in a small proportion of penile tumors is consistent with previous
studies and may be indicative of the rare carcinogenic potential of
these types (5, 22–24).
Regional and racial/ethnic disparities in the incidence of penile
cancer have been observed in the U.S. with higher incidence in
the South and among blacks and Hispanics and lower incidence
in the West and among Asian-Pacific Islanders (1, 25, 26). In our
limited sample, we observed no differences between HPV-positive
and HPV-negative penile cancer cases by age, race/ethnicity, or
population size of geographic region.
We also observed no significant differences in HPV status by
stage,histology,grade,or penile subsite. Notably,nearly all basaloid
and warty tumors, including mixed subtypes, were HPV-positive.
This is consistent with previous studies demonstrating a higher
prevalence of HPV in these histological types (2, 4, 7).
The incidence of invasive penile cancer in the U.S. has sig-
nificantly declined over the past several decades (25, 26). The
reason for this decline is unknown but may be attributed to
population-level changes including decreases in smoking rates
(27) and increases in circumcision in older birth cohorts (28).
A major limitation of this study is the lack of patient information
on other risk factors for penile cancer including sexual history,
smoking, circumcision, and phimosis (4, 8–11). This information
is generally not abstracted by cancer registries. The availability of
such data would permit a more comprehensive evaluation of the
role of HPV relative to these factors.
Human papillomavirus was detected more frequently in the
recently diagnosed cases. A recent study reported that the preva-
lence of HPV in U.S. oropharyngeal cancers significantly increased
over calendar time from 1984 to 2004 (29). It was surmised that
this may reflect increases in high-risk sexual activity and HPV
exposure over time. The authors corrected for potential loss in
assay sensitivity with specimen age. In the present study, preva-
lence estimates were not corrected. Therefore, it is possible that the
observed temporal differences in HPV prevalence were an artifact
due to the relative age of the archival tissue specimens. That is, viral
DNA may have been less readily detected in older specimens due
to degradation of nucleic acid in preserved tissue over time. While
we found no evidence for this, it is hard to completely exclude this
explanation. The ability to examine temporal trends in the present
study is limited by the relatively narrow (8 year) period of diagno-
sis of cases. In addition, because registries used different temporal
sampling frames, it is possible that observed temporal differences
reflect geographic differences. In the present study, HPV preva-
lence is not presented by registry to protect patient confidentiality
given the small number of cases.
In patients with oropharyngeal cancer HPV tumor positiv-
ity predicts a favorable outcome, including overall survival and
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disease-free survival (30–36). Few studies have examined the role
of HPV in penile cancer survival. Lont et al. (6) observed that
penile cancer patients with high-risk human HPV had significantly
higher 5-year survival, and HPV was an independent predictor of
survival after adjustment for age and clinical characteristics (6).
We found no association of HPV status, including any HPV and
HPV 16, with penile cancer survival.
As with other PCR-based studies, we cannot be certain that the
HPV DNA detected was present and causal in the tumor. HPV
infection could have been present in nearby tissue. Evaluation of
other molecular markers of HPV, including p16INK4a and E6/E7
mRNA, may provide important insight into the clinical relevance
of viral detection in penile cancers (37).
Forty-eight percent of penile cancers were positive for HPV 16
or 18, which are included in current vaccines. HPV vaccination
has demonstrated high efficacy for the prevention of genital HPV
infection and external genital lesions in males (38). Nonetheless,
vaccine efficacy for the prevention of penile cancers has not yet
been directly evaluated in clinical trials.
The relatively high prevalence of HPV in our study popula-
tion provides limited evidence of a more prominent and, possibly,
increasing role of infection in penile carcinogenesis in the U.S.
compared to other parts of the world. Population differences in the
prevalence of sexual risks, circumcision, and other factors influ-
encing HPV acquisition and persistence may account for these
results. Our findings would be bolstered by future U.S. studies
which include larger, population-based samples, which are derived
from patients diagnosed with penile cancer over a wider time
period.
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